Share Email Print

Proceedings Paper

40 Hz invisible spectral flicker and its potential use in Alzheimer's light therapy treatment
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Alzheimer’s disease (AD) not only takes an emotional toll on the individual with the disease, their families, relatives, and caretakers, it also has immense socioeconomic consequences on the health care system and society. Moreover, the socioeconomic consequences are expected to increase significantly, thus reducing the social and economic cost of AD is of high importance. Recently, exposure to 40 Hz stroboscopic light therapy, for one hour a day, resulted in slowing the progression of AD in mice and has a considerable potential for treatment in humans. However, exposure to such stroboscopic light carries its own consequences being that it is difficult to implement in a patient’s daily routine, irksome to use, and can cause visual discomfort which may result in a lack of patient adherence.

Here, we demonstrate a novel technology based on controlling multiple single-color LEDs to produce white light where its spectral composition alternates at a given modulation frequency without visible flicker. We coin this technique as Invisible Spectral Flicker (ISF). We present 40 Hz invisible spectral flicker light as a potential alternative in reducing discomfort compared to 40 Hz stroboscopic light, whilst still entraining oscillations in various areas of the brain. Furthermore, we demonstrate a distinct way to generate a 40 Hz metameric light source with the presented color mixing scheme, and validate that the CIE 1931 (x, y) coordinates match for two different spectral power distributions. Finally, we illustrate the light characteristics of seven 40 Hz color fusion light sources and two 40 Hz stroboscopic light sources. The technology presented here will lead to new, and hopefully improved, designs of light therapy systems for the treatment of Alzheimer’s and dementia.

Paper Details

Date Published: 11 March 2020
PDF: 12 pages
Proc. SPIE 11221, Mechanisms of Photobiomodulation Therapy XV, 112210L (11 March 2020); doi: 10.1117/12.2544338
Show Author Affiliations
Marcus S. Carstensen, Technical Univ. of Denmark (Denmark)
Johannes Lindén, Technical Univ. of Denmark (Denmark)
N. Mai Nguyen, Univ. of California, Berkeley (United States)
Henrik E. Hansen, Technical Univ. of Denmark (Denmark)
Gustavo M. Feijóo Carrillo, OptoCeutics ApS (Denmark)
Luna S. Hansen, OptoCeutics ApS (Denmark)
Dennis D. Corell, Technical Univ. of Denmark (Denmark)
Jes Broeng, Technical Univ. of Denmark (Denmark)
Lance J. Kriegsfeld, Univ. of California, Berkeley (United States)
Paul Michael Petersen, Technical Univ. of Denmark (Denmark)

Published in SPIE Proceedings Vol. 11221:
Mechanisms of Photobiomodulation Therapy XV
Michael R. Hamblin; James D. Carroll; Praveen Arany, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?